flunitrazepam 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
diazepam derivatives 1202 1622-62-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • flunitrazepam
  • flunidazepam
  • fluridrazepam
  • flunipam
A benzodiazepine with pharmacologic actions similar to those of DIAZEPAM that can cause ANTEROGRADE AMNESIA. Some reports indicate that it is used as a date rape drug and suggest that it may precipitate violent behavior. The United States Government has banned the importation of this drug.
  • Molecular weight: 313.29
  • Formula: C16H12FN3O3
  • CLOGP: 1.78
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 0
  • TPSA: 78.49
  • ALOGS: -4.56
  • ROTB: 2

Drug dosage:

DoseUnitRoute
1 mg O
1 mg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.00 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.11 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 80 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.90 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.40 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.17 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 25 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Jan. 1, 1976 YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Intentional overdose 133.59 25.04 72 3601 68045 56220349
Neuroleptic malignant syndrome 116.10 25.04 39 3634 11439 56276955
Suicide attempt 107.41 25.04 59 3614 57777 56230617
Altered state of consciousness 106.35 25.04 44 3629 22977 56265417
Overdose 101.93 25.04 71 3602 105759 56182635
Salivary hypersecretion 83.51 25.04 27 3646 7023 56281371
Hepatic function abnormal 68.94 25.04 37 3636 34521 56253873
Extrapyramidal disorder 61.74 25.04 25 3648 12331 56276063
Psychiatric symptom 59.19 25.04 19 3654 4825 56283569
Pneumonia aspiration 51.79 25.04 30 3643 32381 56256013
Loss of consciousness 50.86 25.04 48 3625 109301 56179093
Blood creatine phosphokinase increased 50.39 25.04 28 3645 27924 56260470
Parkinsonism 50.06 25.04 20 3653 9526 56278868
Toxicity to various agents 48.35 25.04 66 3607 224498 56063896
Electrocardiogram QT prolonged 46.40 25.04 34 3639 54554 56233840
Drowning 42.45 25.04 9 3664 447 56287947
Hypothermia 41.72 25.04 19 3654 12451 56275943
Delusion 34.12 25.04 16 3657 11199 56277195
Stevens-Johnson syndrome 33.62 25.04 20 3653 22643 56265751
Peritoneal perforation 33.57 25.04 6 3667 120 56288274
Brain injury 32.23 25.04 13 3660 6342 56282052
Carcinoid tumour of the stomach 31.99 25.04 6 3667 158 56288236
White blood cell count increased 31.67 25.04 25 3648 44734 56243660
Lip erosion 31.44 25.04 8 3665 886 56287508
Malignant catatonia 31.02 25.04 6 3667 187 56288207
Electrocardiogram J wave abnormal 29.84 25.04 4 3669 9 56288385
Aspiration 27.05 25.04 13 3660 9608 56278786
Respiratory depression 26.71 25.04 14 3659 12421 56275973
Depressed level of consciousness 26.63 25.04 25 3648 56408 56231986
Water intoxication 26.27 25.04 6 3667 421 56287973
Cerebral infarction 26.14 25.04 17 3656 22488 56265906
Schizophrenia 25.97 25.04 13 3660 10486 56277908
Pain 25.61 25.04 6 3667 663178 55625216
Thalamic infarction 25.54 25.04 6 3667 476 56287918
Rhabdomyolysis 25.15 25.04 21 3652 40637 56247757

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Neuroleptic malignant syndrome 123.45 21.67 54 3917 16815 31676558
Hepatic function abnormal 78.22 21.67 54 3917 41168 31652205
Altered state of consciousness 74.32 21.67 41 3930 21010 31672363
Pneumonia aspiration 71.75 21.67 50 3921 38676 31654697
Rhabdomyolysis 65.43 21.67 58 3913 63523 31629850
Asphyxia 57.44 21.67 23 3948 5728 31687645
Salivary hypersecretion 57.12 21.67 25 3946 7767 31685606
Blood creatine phosphokinase increased 46.57 21.67 40 3931 41934 31651439
Water intoxication 42.51 21.67 10 3961 411 31692962
Suicide attempt 38.30 21.67 34 3937 37214 31656159
Lymphocyte percentage increased 37.77 21.67 8 3963 202 31693171
White blood cell count increased 36.95 21.67 34 3937 38966 31654407
Toxicity to various agents 35.21 21.67 73 3898 181414 31511959
Sciatic nerve neuropathy 34.41 21.67 6 3965 51 31693322
Delusion 33.31 21.67 20 3951 11977 31681396
Parkinsonism 32.91 21.67 17 3954 7619 31685754
Psychiatric symptom 32.22 21.67 13 3958 3298 31690075
Intentional overdose 31.51 21.67 32 3939 41357 31652016
Sciatic nerve injury 31.35 21.67 6 3965 89 31693284
Stupor 30.83 21.67 12 3959 2772 31690601
Overdose 29.35 21.67 44 3927 84620 31608753
Polydipsia 28.04 21.67 12 3959 3528 31689845
Schizophrenia 24.86 21.67 16 3955 10814 31682559
Neonatal asphyxia 23.60 21.67 6 3965 342 31693031
Persecutory delusion 22.08 21.67 9 3962 2343 31691030

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Neuroleptic malignant syndrome 233.73 23.29 92 7449 25915 70894988
Altered state of consciousness 162.30 23.29 81 7460 39941 70880962
Hepatic function abnormal 139.59 23.29 88 7453 67908 70852995
Salivary hypersecretion 138.48 23.29 52 7489 12873 70908030
Intentional overdose 116.71 23.29 91 7450 98344 70822559
Pneumonia aspiration 113.96 23.29 75 7466 62214 70858689
Suicide attempt 108.59 23.29 80 7461 79430 70841473
Psychiatric symptom 90.80 23.29 32 7509 6612 70914291
Overdose 88.00 23.29 99 7442 169646 70751257
Rhabdomyolysis 87.25 23.29 76 7465 95684 70825219
Blood creatine phosphokinase increased 86.69 23.29 63 7478 61200 70859703
Parkinsonism 80.25 23.29 37 7504 15288 70905615
White blood cell count increased 71.09 23.29 59 7482 69514 70851389
Delusion 69.50 23.29 36 7505 19129 70901774
Extrapyramidal disorder 58.54 23.29 33 7508 20717 70900186
Water intoxication 52.99 23.29 13 7528 756 70920147
Schizophrenia 50.94 23.29 28 7513 16740 70904163
Asphyxia 48.07 23.29 23 7518 10319 70910584
Toxicity to various agents 46.70 23.29 116 7425 382056 70538847
Cerebral infarction 40.87 23.29 35 7506 42974 70877929
Dyspnoea 38.43 23.29 17 7524 770043 70150860
Pain 36.21 23.29 11 7530 628805 70292098
Liver disorder 35.44 23.29 38 7503 61530 70859373
Lymphocyte percentage increased 35.25 23.29 9 7532 616 70920287
Stupor 34.96 23.29 16 7525 6493 70914410
Pyrexia 34.13 23.29 141 7400 606811 70314092
Depressed level of consciousness 33.78 23.29 44 7497 87387 70833516
Lip erosion 32.43 23.29 10 7531 1362 70919541
Electrocardiogram QT prolonged 32.22 23.29 42 7499 83475 70837428
Sudden death 30.53 23.29 22 7519 21042 70899861
Ileus paralytic 30.44 23.29 16 7525 8745 70912158
Loss of consciousness 30.14 23.29 57 7484 155659 70765244
Polydipsia 29.92 23.29 14 7527 5974 70914929
Aspiration 29.20 23.29 20 7521 17655 70903248
Hypothermia 28.69 23.29 21 7520 20573 70900330
Peritoneal perforation 28.64 23.29 6 7535 170 70920733
Hallucination, auditory 28.54 23.29 20 7521 18308 70902595
Carcinoid tumour of the stomach 28.06 23.29 6 7535 188 70920715
Neutrophil count increased 27.91 23.29 23 7518 26772 70894131
Electrocardiogram J wave abnormal 27.88 23.29 4 7537 9 70920894
Heat illness 27.74 23.29 7 7534 457 70920446
Glucose tolerance impaired 25.28 23.29 13 7528 6793 70914110
Somnolence 24.75 23.29 64 7477 215542 70705361
Sciatic nerve neuropathy 24.35 23.29 6 7535 355 70920548
Restlessness 24.24 23.29 26 7515 42102 70878801
Persecutory delusion 23.93 23.29 11 7530 4506 70916397
Fatigue 23.61 23.29 32 7509 824287 70096616
Insomnia 23.32 23.29 63 7478 217743 70703160

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N05CD03 NERVOUS SYSTEM
PSYCHOLEPTICS
HYPNOTICS AND SEDATIVES
Benzodiazepine derivatives
MeSH PA D014151 Anti-Anxiety Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D018682 GABA Agents
MeSH PA D018757 GABA Modulators
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D011619 Psychotropic Drugs
MeSH PA D014149 Tranquilizing Agents
CHEBI has role CHEBI:35474 anti-anxiety agents
CHEBI has role CHEBI:35717 hypnotics
CHEBI has role CHEBI:91016 GABAA receptor agonists

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 1.89 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Gamma-aminobutyric acid receptor subunit alpha-1 Ion channel ALLOSTERIC MODULATOR Ki 8.28 IUPHAR IUPHAR
Gamma-aminobutyric acid receptor subunit alpha-2 Ion channel ALLOSTERIC MODULATOR Ki 8.28 IUPHAR IUPHAR
Gamma-aminobutyric acid receptor subunit alpha-3 Ion channel ALLOSTERIC MODULATOR Ki 7.80 IUPHAR IUPHAR
Gamma-aminobutyric acid receptor subunit alpha-5 Ion channel ALLOSTERIC MODULATOR Ki 8.26 IUPHAR IUPHAR
GABA-A receptor alpha-1/beta-2/gamma-2 Ion channel Ki 8.70 WOMBAT-PK
GABA-A receptor alpha-2/beta-3/gamma-2 Ion channel Ki 8.70 WOMBAT-PK
GABA-A receptor alpha-3/beta-3/gamma-2 Ion channel Ki 8.35 WOMBAT-PK
GABA-A receptor alpha-5/beta-3/gamma-2 Ion channel Ki 8.84 WOMBAT-PK
GABA-A receptor alpha-1/beta-2/gamma-3 Ion channel Ki 7.46 WOMBAT-PK
GABA-A receptor alpha-1/beta-3/gamma-2 Ion channel Ki 8.47 WOMBAT-PK
GABA A receptor alpha-3/beta-2/gamma-2 Ion channel Ki 8.82 WOMBAT-PK
GABA A receptor alpha-3/beta-2/gamma-3 Ion channel Ki 7.50 WOMBAT-PK
GABA A receptor alpha-5/beta-3/gamma-3 Ion channel Ki 8.42 WOMBAT-PK
GABA A receptor alpha-5/beta-2/gamma-2 Ion channel Ki 9 WOMBAT-PK
GABA A receptor alpha-5/beta-2/gamma-3 Ion channel Ki 8.42 WOMBAT-PK
GABA-A receptor; anion channel Ion channel IC50 8.82 CHEMBL

External reference:

IDSource
N0000166924 NUI
D01230 KEGG_DRUG
C0016296 UMLSCUI
CHEBI:31622 CHEBI
CHEMBL13280 ChEMBL_ID
DB01544 DRUGBANK_ID
D005445 MESH_DESCRIPTOR_UI
3380 PUBCHEM_CID
4193 IUPHAR_LIGAND_ID
2951 INN_ID
620X0222FQ UNII
4460 RXNORM
004091 NDDF
387573007 SNOMEDCT_US
96237009 SNOMEDCT_US

Pharmaceutical products:

None